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Seminal vesicle (SV) adenocarcinoma is a rare and poorly understood malignancy. Symptoms are non-
speciﬁc and prognosis is extremely poor. Herein we present a case report of a primary SV clear cell
adenocarcinoma with bilateral orbital metastases at the time of initial presentation treated with
multimodal therapy including radiotherapy and multi-drug chemotherapy.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Seminal vesicle (SV) adenocarcinoma is a rare and poorly un-
derstood malignancy. Symptoms are non-speciﬁc and patients
often present with advanced or metastatic disease. Prognosis is
poor with w95% dying within 3 years of diagnosis.1 We present a
case report of a primary SV clear cell adenocarcinomawith bilateral
orbital metastases at the time of presentation.Case report
A 29-year-old man initially presented to his primary care
physician (PCP) with blurriness and pain in his right eye, bloody
discharge per urethra, and a weak urinary stream. For the bloody
discharge and change in his voiding patterns he was prescribed
antibiotics. For his eye pain and blurry vision he was referred to an
Ophthalmologist. On examination a tumor was discovered in his
right eye and a smaller tumor in his left eye. A computed tomog-
raphy (CT) scan of the head showed no additional disease. Further
staging with a CT of the chest, abdomen, and pelvis revealed an
11  7 cm partially cystic heterogeneous pelvic mass of uncertain
origin posterior to the base of the bladder (Fig.1). Hewas referred to
urology due to his persistent bloody discharge and newly diag-
nosed pelvic mass. Digital rectal exam (DRE) revealed a large and
ﬁrm mass indistinguishable from the prostate gland. Lab workþ1 215 662 7413.
(M.E. Sterling).
Inc. This is an open access article urevealed an elevated CA-125 at 40 U/mL and an undetectable
prostate speciﬁc antigen (PSA) (<0.2 ng/mL).
He underwent a cystoscopic evaluation revealing a heteroge-
neous prostatic urethra with multiple abnormal protrusions and a
mass effect on the bladder displacing the trigone off of the midline,
but no mucosal lesions concerning for urothelial cancer. The
abnormal prostatic protrusions were biopsied. We then performed
a transrectal ultrasound-guided biopsy of the pelvic mass. Both
biopsies revealed a poorly differentiated adenocarcinoma with
papillary features, mucin production, and clear cell histology.
Immunohistochemistry was performed and was positive for CK7
(Fig. 2), AE1-3, and Cam5.2. Tumor cells were negative for CK20
(Fig. 3), PSA, PSAP, Desmin, smooth muscle actin, CD30, PLAP, AFP,
CD117, CD34, and S100. Based on all of these immunohistochem-
istry markers, the pathologic diagnosis was most consistent with a
poorly differentiated carcinoma originating from the SV.
Given orbital and lymph node metastasis, upfront chemo-
therapy with carboplatin/paclitaxel was initiated and he completed
4 cycles. He underwent radiotherapy to his orbital lesions and large
pelvic mass. He later developed a rectovesical ﬁstula and under-
went an ileostomy diversion. His disease burden was stable for
15 months until he developed local and distant progression. He
continued to progress despite treatment and palliative care was
provided. He expired 4.5 years after his initial diagnosis.Discussion
Since primary SV adenocarcinoma was ﬁrst described, only
about 50 cases have been reported in the literature.1,2 Despitender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Contrast enhanced CT scan of the pelvis showing a large, heterogeneous
mass.
Figure 3. CK20 negative staining of transrectal biopsy of pelvic mass.
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marily one of exclusion.
Symptoms do not typically develop until late in the clinical
course and are non-speciﬁc. The most commonly reported symp-
toms are hematospermia, hematuria, bladder outlet obstruction,
and pelvic pain.2 Because symptoms are initially non-speciﬁc or
non-existent, diagnosis is delayed and most patients present with
advanced or metastatic disease, often to locoregional lymph nodes.
Our patient initially presented with bilateral orbital metastasis,
which we believe is the ﬁrst reported case of its kind. Physical exam
typically reveals a non-tender mass on DRE, which may be indis-
tinguishable from the prostate. It is thus of great importance to rule
out other primary malignancies such as prostate, bladder, or colo-
rectal cancers since SV carcinomas are often locally advanced at
presentation and appear similar to these other malignancies.2
Imaging is critical in the diagnosis and helps rule out other
potential malignancies. CT, magnetic resonance imaging (MRI), or
transrectal ultrasound may all be useful in determining the diag-
nosis.2 PET imaging can help exclude distant metastasis 3,4 or
determine the response to treatment.4 Cystoscopy and/or
sigmoidoscopy, while non-speciﬁc, may be considered.
A laboratory evaluation should be obtained. Serum CA-125
levels are generally elevated for primary SV carcinomas, whereas
PSA and CEA are typically normal.2 Diagnosis is often conﬁrmed via
transrectal ultrasound-guided biopsies.2Figure 2. CK7 positive staining of transrectal biopsy of pelvic mass.Even with improvements in radiologic studies, pathologic
analysis remains the mainstay for diagnosis (Figs. 2 and 3).
Adenocarcinoma is the most common malignant lesion of the SV
whereas cystadenoma and mesenchymal tumors represent the
most common benign lesions.5 Immunohistochemistry is critical in
differentiating SV carcinoma from cancers of the prostate, bladder,
or rectum. SV carcinomas stain strongly positive for CK7 (Fig. 2) and
CA 125, negative for CK20 (Fig. 3), and variable for CEA.1e3 Further
study will be needed to delineate which pathologic features
correlate with prognosis.
There are no established guidelines for the treatment of primary
SV adenocarcinoma. When the disease remains clinically localized,
complete surgical resection is the mainstay of treatment. This can
range from a simple excision to a complete pelvic exenteration
depending on the location and size of the tumor.5
Multimodal therapy is the rule for more advanced cases of SV
carcinoma. Radiation therapy is not effective for local disease con-
trol; however, it may be utilized as an adjunctive therapy in those
with unresectable tumors or positive margins.5 Androgen depri-
vation therapy has been used as an adjunct with reports suggesting
improvements in survival.1,5 For cases presenting with advanced or
metastatic disease, chemotherapy can be tried, although its use is
controversial and there exists no deﬁnitive recommendation on
which regimen is best. Thyavihally et al, attempted 5-ﬂuorouracil,
leucovorin, and oxaliplatin in addition to androgen deprivation
therapy with some success.5
In our patient, no surgical therapy was attempted given the
widespread nature of his disease, but he responded well to targeted
radiation therapy and multidrug chemotherapy with survival of
4.5 years from the time of diagnosis. Although his course was
complicated, it shows that treating this rare and aggressive cancer
withmultiple treatmentmodalitiesmay provide the best outcomes.Conclusion
Given the rarity of the condition, non-speciﬁc symptomatology,
and aggressive nature of the disease, SV cancers remain a chal-
lenging clinical entity for the practicing urologist.
Early diagnosis and aggressive extirpative therapy offer the best
chance at a durable response.Conﬂicts of interest
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